WO2017019673A3 - Méthodes permettant de diagnostiquer et de traiter une maladie inflammatoire de l'intestin - Google Patents

Méthodes permettant de diagnostiquer et de traiter une maladie inflammatoire de l'intestin Download PDF

Info

Publication number
WO2017019673A3
WO2017019673A3 PCT/US2016/044022 US2016044022W WO2017019673A3 WO 2017019673 A3 WO2017019673 A3 WO 2017019673A3 US 2016044022 W US2016044022 W US 2016044022W WO 2017019673 A3 WO2017019673 A3 WO 2017019673A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inflammatory bowel
diagnosing
bowel disease
treating inflammatory
Prior art date
Application number
PCT/US2016/044022
Other languages
English (en)
Other versions
WO2017019673A2 (fr
Inventor
Teresa Ramirez MONTAGUT
Akiko CHAI
Franklin FUH
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Priority to JP2018503499A priority Critical patent/JP2018521661A/ja
Priority to CN201680055933.8A priority patent/CN108139385A/zh
Priority to EP16750314.3A priority patent/EP3329276A2/fr
Publication of WO2017019673A2 publication Critical patent/WO2017019673A2/fr
Publication of WO2017019673A3 publication Critical patent/WO2017019673A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

L'invention porte sur des biomarqueurs prédictifs de la réactivité à des antagonistes de l'intégrine bêta 7, y compris à des anticorps de sous-unités de l'intégrine anti-bêta 7, et sur des procédés d'utilisation de tels biomarqueurs. De plus, l'invention concerne des méthodes de traitement de troubles inflammatoires gastro-intestinaux, tels que les maladies inflammatoires de l'intestin, y compris la colite ulcéreuse et la maladie de Crohn. L'invention concerne également des méthodes d'utilisation de tels biomarqueurs prédictifs pour le traitement de maladies inflammatoires de l'intestin, y compris de la colite ulcéreuse et de la maladie de Crohn.
PCT/US2016/044022 2015-07-27 2016-07-26 Méthodes permettant de diagnostiquer et de traiter une maladie inflammatoire de l'intestin WO2017019673A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2018503499A JP2018521661A (ja) 2015-07-27 2016-07-26 炎症性腸疾患の診断及び治療方法
CN201680055933.8A CN108139385A (zh) 2015-07-27 2016-07-26 用于诊断和治疗炎症性肠病的方法
EP16750314.3A EP3329276A2 (fr) 2015-07-27 2016-07-26 Méthodes de diagnostic et de traitement de la maladie intestinale inflammatoire

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562197293P 2015-07-27 2015-07-27
US62/197,293 2015-07-27
US201562241331P 2015-10-14 2015-10-14
US62/241,331 2015-10-14

Publications (2)

Publication Number Publication Date
WO2017019673A2 WO2017019673A2 (fr) 2017-02-02
WO2017019673A3 true WO2017019673A3 (fr) 2017-06-08

Family

ID=56618256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/044022 WO2017019673A2 (fr) 2015-07-27 2016-07-26 Méthodes permettant de diagnostiquer et de traiter une maladie inflammatoire de l'intestin

Country Status (4)

Country Link
EP (1) EP3329276A2 (fr)
JP (1) JP2018521661A (fr)
CN (1) CN108139385A (fr)
WO (1) WO2017019673A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110283889B (zh) * 2019-07-22 2020-10-13 中南大学 一种双基因监控反应体系、试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322556A1 (fr) * 2004-09-03 2011-05-18 Genentech, Inc. Antagonistes anti-béta 7 humanisés et utilisations associées
WO2013037970A1 (fr) * 2011-09-15 2013-03-21 Nogra Pharma Limited Méthodes pour surveiller la réactivité à un traitement anti-smad7
WO2014160753A1 (fr) * 2013-03-27 2014-10-02 Genentech, Inc. Utilisation de biomarqueurs pour évaluer le traitement de troubles gastro-intestinaux inflammatoires par des antagonistes de l'intégrine bêta7

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322556A1 (fr) * 2004-09-03 2011-05-18 Genentech, Inc. Antagonistes anti-béta 7 humanisés et utilisations associées
WO2013037970A1 (fr) * 2011-09-15 2013-03-21 Nogra Pharma Limited Méthodes pour surveiller la réactivité à un traitement anti-smad7
WO2014160753A1 (fr) * 2013-03-27 2014-10-02 Genentech, Inc. Utilisation de biomarqueurs pour évaluer le traitement de troubles gastro-intestinaux inflammatoires par des antagonistes de l'intégrine bêta7

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANIKA FISCHER ET AL: "Differential effects of [alpha]4[beta]7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo", GUT, vol. 65, no. 10, 24 July 2015 (2015-07-24), UK, pages 1642 - 1664, XP055306066, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2015-310022 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2003, HART AILSA ET AL: "INTESTINAL HOMING MEMORY T LYMPHOCYTES PRODUCE INCREASED TUMOUR NECROSIS FACTOR-ALPHA DURING RELAPSE OF ULCERATIVE COLITIS: PROSPECTIVE STUDY OF PATIENTS IN REMISSION AND AT RELPASE.", XP002768300, Database accession no. PREV200300572617 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2015 (2015-04-01), LORD JAMES D ET AL: "Effect of Vedolizumab on Circulating Lymphocyte Subsets in IBD James D. Lord, Donna Shows", XP002768299, Database accession no. PREV201500715500 *
FRANKLIN FUH: "Inflammatory Bowel Disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 110, 21 October 2015 (2015-10-21), US, pages S766 - S847, XP055306057, ISSN: 0002-9270, DOI: 10.1038/ajg.2015.276 *

Also Published As

Publication number Publication date
EP3329276A2 (fr) 2018-06-06
CN108139385A (zh) 2018-06-08
JP2018521661A (ja) 2018-08-09
WO2017019673A2 (fr) 2017-02-02

Similar Documents

Publication Publication Date Title
MX2022010809A (es) Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales.
WO2014186728A3 (fr) Procédés pour le diagnostic et le traitement d'une affection abdominale inflammatoire
WO2016086036A3 (fr) Méthodes et compositions pour radiomarquage au 18f de produits biologiques
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
WO2016094837A3 (fr) Anticorps anti-c10orf54 et leurs utilisations
WO2016034591A3 (fr) Pores mutants
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
AR092908A1 (es) Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria
WO2014186599A3 (fr) Anticorps anti-facteur c1s du complément et leurs utilisations
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
WO2015173633A3 (fr) Marqueurs de thérapie hdl
CO2019006257A2 (es) Probiotics for use in diverticulosis and diverticular disease
WO2012047631A3 (fr) Compositions et procédés utiles dans le traitement et le diagnostic d'une maladie intestinale inflammatoire
WO2016014434A3 (fr) Anticorps anti-cd74, compositions comprenant des anticorps anti-cd74 et procédés d'utilisation d'anticorps anti-cd74
ZA201901826B (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease
WO2017066712A3 (fr) Modulateurs de maladie de télomères
WO2016106343A8 (fr) Organismes probiotiques pour le diagnostic, la surveillance et le traitement de la maladie intestinale inflammatoire
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
PH12018500578A1 (en) Methods of treating inflammatory diseases
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
WO2015138532A3 (fr) Méthodes de traitement de la fibrose rénale
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
WO2015153997A3 (fr) Anticorps anti-notch 3 et leurs utilisations
WO2018071504A3 (fr) Méthodes de traitement de maladies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16750314

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018503499

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016750314

Country of ref document: EP